Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Efforts to develop neuroprotective therapy for Parkinson disease (PD) are focusing on the
early stages of disease, which offer the best opportunity to intervene. Early PD can be …

It has been reported that disordered Cu metabolism is associated with several
neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease …

Previous studies have shown that aerobic exercise is an effective way to improve symptoms
of Parkinson's disease (PD). The aim of this study [PROSPERO CRD42022340730] was to …

Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

Abstract See Gratwicke and Foltynie (doi: 10.1093/brain/awx333) for a scientific commentary
on this article. Cognitive impairments are a prevalent and disabling non-motor complication …

Background Prognosticating the course of diseases to inform decision-making is a key
component of intensive care medicine. For several applications in medicine, new methods …

Adiponectin (ADPN) is a plasma protein secreted by adipose tissue showing pleiotropic
effects with anti-diabetic, anti-atherogenic, and anti-inflammatory properties. Initially, it was …

Background: Cognitive dysfunction is one of the most prevalent non-motor symptoms in
Parkinson's disease (PD), often experienced as more debilitating for patients and caregivers …

Introduction Identification of factors associated with progression of cognitive symptoms in
Parkinson's disease (PD) is important for treatment planning, clinical care, and design of …